CNTB
Connect Biopharma Holdings Limited Ordinary Shares
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
CNTB Stock Analysis: Buy, Sell, or Hold?
$0.67
-0.02 (-3.43%)
▼
5d:
-9.07%
30d:
-26.81%
90d:
-73.91%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
40/100
Position
OVERSOLD
30-Day Fair Range
$0.75 – $0.90
Position: OVERSOLD
Forward P/E & Valuation
-0.8x
Next 12M consensus est.
Wall Street Target
$6.00
+801.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$0.66 / $0.87
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: CNTB shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When CNTB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: CNTB is currently trading at $0.67, which is considered oversold relative to its 30-day fair value range of $0.75 to $0.90.
Technical Outlook: Technically, CNTB is in a strong downtrend. The price is currently testing key support at $0.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: CNTB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+801.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNTB is in a strong downtrend. The price is currently testing key support at $0.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: CNTB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+801.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.75 -
$0.90
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
Trading Range & Key Levels
30-Day Trading Range
$0.75 -
$0.90
Current vs Trading Range
OVERSOLD
Support Level
$0.66
Resistance Level
$0.87
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 801.8% below Wall St target ($6.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-0.80
Wall Street Target
$6.00
(+801.8%)
Revenue Growth (YoY)
5666.7%
Share CNTB Analysis
Share this live CNTB analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (CNTB)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Bullish sentiment on StockTwits regarding $CNTB remains strong despite mixed Phase 2 trial results for Connect Biopharma Holdings. The latest article from Yahoo Finance discusses how analysts have revised their price targets following the trial, with a shift towards a more cautious stance due to added clinical and execution risk.
Key Retail Themes:
Phase 2 trial results
Price target revisions
Analyst opinions
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 8:06 PM ET
Data refreshes hourly during market hours. Next update: 9:06 PM
Data refreshes hourly during market hours. Next update: 9:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$122 | 44 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive CNTB Research Pages
